Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Genprex	Enlivex Therapeutics	Abeona Therapeutics	Aptinyx	NeuBase Therapeutics
Symbol	NASDAQ:GNPX	NASDAQ:ENLV	NASDAQ:ABEO	NASDAQ:APTX	NASDAQ:NBSE
Price Information
Current Price	$3.84	$10.14	$1.61	$2.77	$5.76
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.2	1.4	1.6	1.4	1.3
Analysis Score	3.5	3.5	3.4	3.4	3.5
Community Score	2.4	3.4	3.0	2.7	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.8	0.8	0.0
Earnings & Valuation Score	0.0	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$6.00	$33.00	$5.17	$11.67	$17.33
% Upside from Price Target	56.25% upside	225.44% upside	220.91% upside	321.18% upside	200.93% upside
Trade Information
Market Cap	$167.05 million	$160.59 million	$150.54 million	$182.16 million	$139.08 million
Beta	-0.57	1.14	1.69	1.47	0.41
Average Volume	1,444,666	400,716	3,684,309	535,219	299,463
Sales & Book Value
Annual Revenue	N/A	N/A	$3 million	$3.67 million	N/A
Price / Sales	N/A	N/A	53.15	50.55	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.15 per share	$1.09 per share	$2.13 per share	$2.31 per share	$1.35 per share
Price / Book	N/A	N/A	0.76	1.20	N/A
Profitability
Net Income	$-10,650,000.00	$-9,380,000.00	$-76,280,000.00	$-57,410,000.00	$-17,390,000.00
EPS	($0.67)	($1.11)	($1.51)	($1.71)	($0.89)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	∞	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	-2,108.05%	N/A
Return on Equity (ROE)	-81.49%	-34.60%	-37.97%	-46.43%	-90.43%
Return on Assets (ROA)	-79.54%	-28.47%	-28.76%	-44.60%	-77.20%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.02%	N/A	N/A	N/A
Current Ratio	60.40%	7.23%	2.70%	26.50%	10.42%
Quick Ratio	58.58%	7.23%	2.70%	26.50%	10.42%
Ownership Information
Institutional Ownership Percentage	12.50%	2.39%	36.47%	43.89%	28.98%
Insider Ownership Percentage	13.05%	N/A	19.10%	8.58%	24.00%
Miscellaneous
Employees	8	36	N/A	43	15
Shares Outstanding	43.28 million	15.76 million	99.04 million	66.97 million	23.18 million
Next Earnings Date	5/13/2021 (Estimated)	5/17/2021 (Estimated)	5/5/2021 (Estimated)	5/13/2021 (Estimated)	5/13/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Expected to Post Earnings of -$0.23 Per Share americanbankingnews.com - April 21 at 4:24 PM
	12-month price target for NeuBase Therapeutics, Inc. (NASDAQ:NBSE) now sits at $18 marketingsentinel.com - April 17 at 3:12 PM
	Coya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors finance.yahoo.com - April 14 at 9:04 AM
	NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases finance.yahoo.com - April 8 at 9:28 AM
	Zacks: Analysts Expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Will Announce Earnings of -$0.23 Per Share americanbankingnews.com - April 4 at 8:42 AM
	Here's What NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Shareholder Ownership Structure Looks Like finance.yahoo.com - March 19 at 12:04 PM
	NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical ... apnews.com - March 17 at 10:05 AM
	NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference finance.yahoo.com - March 16 at 8:19 AM
	NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 Nasdaq: NBSE compsmag.com - March 9 at 6:13 PM
	NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 finance.yahoo.com - March 9 at 8:12 AM
	NeuBase Therapeutics Inc. barrons.com - March 5 at 1:27 PM
	BRIEF—NeuBase buys gene modulating technology from Vera Therapeutics thepharmaletter.com - February 12 at 7:40 PM
	NeuBase: Fiscal 1Q Earnings Snapshot \| Raleigh News & Observer newsobserver.com - February 11 at 7:39 PM
	NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021 finance.yahoo.com - February 11 at 7:39 PM
	NBSE Feb 2021 17.500 call uk.finance.yahoo.com - February 9 at 5:38 PM
	NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics markets.businessinsider.com - January 28 at 8:58 AM
	NBSE Feb 2021 12.500 put uk.finance.yahoo.com - January 27 at 5:16 PM
	NBSE May 2021 2.500 call uk.finance.yahoo.com - January 26 at 10:47 PM
	NBSE Aug 2021 7.500 call uk.finance.yahoo.com - January 26 at 5:47 PM
	Is Neubase Therapeutics (NBSE) Stock a Buy For 2021? finance.yahoo.com - January 22 at 12:49 AM
	NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference finance.yahoo.com - January 11 at 8:33 AM
	NeuBase: Fiscal 4Q Earnings Snapshot \| Raleigh News & Observer newsobserver.com - December 23 at 6:55 PM
	NeuBase: Fiscal 4Q Earnings Snapshot \| Charlotte Observer charlotteobserver.com - December 23 at 6:55 PM
	NeuBase: Fiscal 4Q Earnings Snapshot sfgate.com - December 23 at 6:55 PM
	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020 finance.yahoo.com - December 23 at 6:55 PM

Date	Company	Brokerage	Action
1/26/2021	Genprex	National Securities	Initiated Coverage
5/26/2020	Genprex	Noble Financial	Reiterated Rating
4/22/2020	Genprex	Alliance Global Partners	Initiated Coverage
4/1/2019	Genprex	Maxim Group	Downgrade
3/2/2021	Enlivex Therapeutics	HC Wainwright	Boost Price Target
3/29/2021	Abeona Therapeutics	SVB Leerink	Reiterated Rating
11/11/2020	Abeona Therapeutics	B. Riley	Reiterated Rating
11/10/2020	Abeona Therapeutics	Cantor Fitzgerald	Upgrade
5/8/2020	Abeona Therapeutics	Royal Bank of Canada	Lower Price Target
5/7/2020	Abeona Therapeutics	Mizuho	Reiterated Rating
1/29/2021	Aptinyx	JPMorgan Chase & Co.	Downgrade
10/27/2020	Aptinyx	Piper Sandler	Initiated Coverage
10/21/2020	Aptinyx	Cowen	Reiterated Rating
10/1/2020	Aptinyx	William Blair	Reiterated Rating
8/14/2020	Aptinyx	BMO Capital Markets	Reiterated Rating
7/1/2020	Aptinyx	SunTrust Banks	Initiated Coverage
9/12/2019	Aptinyx	Wedbush	Initiated Coverage
3/18/2021	NeuBase Therapeutics	Oppenheimer	Reiterated Rating
8/14/2020	NeuBase Therapeutics	Chardan Capital	Reiterated Rating
2/6/2020	NeuBase Therapeutics	Guggenheim	Initiated Coverage
9/24/2019	NeuBase Therapeutics	BTIG Research	Initiated Coverage

(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources